@article{SchuesslerOppermannKreuzeretal.1986, author = {Sch{\"u}ssler, Ulrich and Oppermann, Uwe and Kreuzer, Hans and Seidel, Eberhard and Okrusch, Martin and Lenz, Karl-Ludwig and Raschka, Helmut}, title = {Zur Altersstellung des ostbayerischen Kristallins - Ergebnisse neuer K-Ar Datierungen}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-31778}, year = {1986}, abstract = {No abstract available}, language = {de} } @article{KreuzerSeidelSchuessleretal.1989, author = {Kreuzer, Hans and Seidel, Eberhard and Sch{\"u}ssler, Ulrich and Okrusch, Martin and Lenz, Karl-Ludwig and Raschka, Helmut}, title = {K-Ar geochronology of different tectonic units at the northeastern margin of the Bohemian Massif}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-31811}, year = {1989}, abstract = {No abstract available}, language = {en} } @article{EngelhardtTerposKleberetal.2014, author = {Engelhardt, Monika and Terpos, Evangelos and Kleber, Martina and Gay, Francesca and W{\"a}sch, Ralph and Morgan, Gareth and Cavo, Michele and van de Donk, Niels and Beilhack, Andreas and Bruno, Benedetto and Johnsen, Hans Erik and Hajek, Roman and Driessen, Christoph and Ludwig, Heinz and Beksac, Meral and Boccadoro, Mario and Straka, Christian and Brighen, Sara and Gramatzki, Martin and Larocca, Alessandra and Lokhorst, Henk and Magarotto, Valeria and Morabito, Fortunato and Dimopoulos, Meletios A. and Einsele, Hermann and Sonneveld, Pieter and Palumbo, Antonio}, title = {European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma}, series = {Haematologica}, volume = {99}, journal = {Haematologica}, number = {2}, doi = {10.3324/haematol.2013.099358}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117477}, pages = {232-242}, year = {2014}, abstract = {Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and for cytogenetically defined high-versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease and preferably in the context of a clinical trial (2B). Thalidomide (1B) or lenalidomide (1A) maintenance increases progression-free survival and possibly overall survival (2B). Bortezomib-based regimens are a valuable consolidation option, especially for patients who failed excellent response after autologous stem cell transplantation (2A). Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care for transplant-ineligible patients (1A). Melphalan-prednisone-lenalidomide with lenalidomide maintenance increases progression-free survival, but overall survival data are needed. New data from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached its primary end point of a statistically significant improvement in progression-free survival as compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B).}, language = {en} } @phdthesis{Gehlen2005, author = {Gehlen, Martin Ludwig}, title = {Kontrollierte Expansion von Insulin produzierenden Beta-Zellen des endokrinen Pankreas durch das Protein p8}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-12027}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2005}, abstract = {p8 ist ein vor einigen Jahren erstmals im Zusammenhang mit Pankreatitis beschriebenes 80 Aminos{\"a}uren langes Protein, das im exokrinen Pankreas mit vermehrtem Zellwachstum assoziiert ist. Wir konnten p8 auch in beta-Zellen des endokrinen Pankreas nachweisen. Um Informationen {\"u}ber die subzellul{\"a}re Lokalisation zu erhalten, wurde ein Plasmid, das f{\"u}r ein Fusionsprotein aus p8 und GFP (gr{\"u}n fluoreszierendes Protein) kodiert, kloniert und in verschiedene Ziellinien transfiziert. Die Ergebnisse dieser Versuche sprechen daf{\"u}r, dass p8 ein nukle{\"a}res Protein ist. Durch ein Deletionskonstrukt des Fusionsproteins wurde ein nukle{\"a}res Lokalisationssignal (NLS) am C-terminalen Ende des Proteins identifiziert. Um weitere Informationen {\"u}ber Funktion und Wirkungsweise von p8 zu erhalten, wurden induzierbar stabile INS-1-Zellen (beta-Zelllinie) etabliert. Stimulation dieser Zellen mit IPTG f{\"u}hrte zu einer 5fachen {\"U}berexpression von p8. Die Zellzahl der p8-{\"u}berexprimierenden Zellen und die der nicht-p8-{\"u}berexprimierenden Zellen wurde zeitabh{\"a}ngig verglichen. Je nach Versuchsaufbau wurden nach 96 Stunden Zellwachstum unter p8-{\"U}berexpression 31\% bis 37\% mehr Zellen als in dem Vergleichskollektiv ohne p8-{\"U}berexpression ermittelt. Von Seufert et al. wurden in den Zellmedien der p8 {\"u}berexprimierenden stabilen INS-1-Zellen kumulativ erh{\"o}hte Insulin-Spiegel gemessen. Dieses spricht daf{\"u}r, dass {\"U}berexpression von p8 in beta-Zellen Proliferation ausloest, nicht aber zu einem Differenzierungsverlust f{\"u}hrt. Unsere Untersuchungen n{\"a}hren die Hoffnung, dass in Zukunft mit Hilfe von p8 Spender-beta-Zellen in vitro vermehrt und im Rahmen einer Zelltherapie einem Diabetiker transplantiert werden k{\"o}nnten.}, language = {de} } @article{StanglHaasEichneretal.2020, author = {Stangl, Stephanie and Haas, Kirsten and Eichner, Felizitas A. and Grau, Anna and Selig, Udo and Ludwig, Timo and Fehm, Tanja and St{\"u}bner, Tanja and Rashid, Asarnusch and Kerscher, Alexander and Bargou, Ralf and Hermann, Silke and Arndt, Volker and Meyer, Martin and Wildner, Manfred and Faller, Hermann and Schrauder, Michael G. and Weigel, Michael and Schlembach, Ulrich and Heuschmann, Peter U. and W{\"o}ckel, Achim}, title = {Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease — the "Breast cancer care for patients with metastatic disease" (BRE-4-MED) registry}, series = {Pilot and Feasibility Studies}, volume = {6}, journal = {Pilot and Feasibility Studies}, doi = {10.1186/s40814-019-0541-3}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229149}, year = {2020}, abstract = {Background: Patients with metastatic breast cancer (MBC) are treated with a palliative approach with focus oncontrolling for disease symptoms and maintaining high quality of life. Information on individual needs of patients andtheir relatives as well as on treatment patterns in clinical routine care for this specific patient group are lacking or arenot routinely documented in established Cancer Registries. Thus, we developed a registry concept specifically adaptedfor these incurable patients comprising primary and secondary data as well as mobile-health (m-health) data. Methods: The concept for patient-centered "Breast cancer care for patients with metastatic disease"(BRE-4-MED)registry was developed and piloted exemplarily in the region of Main-Franconia, a mainly rural region in Germanycomprising about 1.3 M inhabitants. The registry concept includes data on diagnosis, therapy, progression, patient-reported outcome measures (PROMs), and needs of family members from several sources of information includingroutine data from established Cancer Registries in different federal states, treating physicians in hospital as well as inoutpatient settings, patients with metastatic breast cancer and their family members. Linkage with routine cancerregistry data was performed to collect secondary data on diagnosis, therapy, and progression. Paper and online-basedquestionnaires were used to assess PROMs. A dedicated mobile application software (APP) was developed to monitorneeds, progression, and therapy change of individual patients. Patient's acceptance and feasibility of data collection inclinical routine was assessed within a proof-of-concept study. Results: The concept for the BRE-4-MED registry was developed and piloted between September 2017 and May 2018.In total n= 31 patients were included in the pilot study, n= 22 patients were followed up after 1 month. Recordlinkage with the Cancer Registries of Bavaria and Baden-W{\"u}rttemberg demonstrated to be feasible. The voluntary APP/online questionnaire was used by n= 7 participants. The feasibility of the registry concept in clinical routine waspositively evaluated by the participating hospitals. Conclusion: The concept of the BRE-4-MED registry provides evidence that combinatorial evaluation of PROMs, needsof family members, and raising clinical parameters from primary and secondary data sources as well as m-healthapplications are feasible and accepted in an incurable cancer collective.}, language = {en} } @article{SchlinkertLudwigBataryetal.2016, author = {Schlinkert, Hella and Ludwig, Martin and Bat{\´a}ry, P{\´e}ter and Holzschuh, Andrea and Kov{\´a}cs-Hosty{\´a}nszki, Anik{\´o} and Tscharntke, Teja and Fischer, Christina}, title = {Forest specialist and generalist small mammals in forest edges and hedges}, series = {Wildlife Biology}, volume = {22}, journal = {Wildlife Biology}, number = {3}, doi = {10.2981/wlb.00176}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-168333}, pages = {86-94}, year = {2016}, abstract = {Agricultural intensification often leads to fragmentation of natural habitats, such as forests, and thereby negatively affects forest specialist species. However, human introduced habitats, such as hedges, may counteract negative effects of forest fragmentation and increase dispersal, particularly of forest specialists. We studied effects of habitat type (forest edge versus hedge) and hedge isolation from forests (connected versus isolated hedge) in agricultural landscapes on abundance, species richness and community composition of mice, voles and shrews in forest edges and hedges. Simultaneously to these effects of forest edge/hedge type we analysed impacts of habitat structure, namely percentage of bare ground and forest edge/hedge width, on abundance, species richness and community composition of small mammals. Total abundance and forest specialist abundance (both driven by the most abundant species Myodes glareolus, bank vole) were higher in forest edges than in hedges, while hedge isolation had no effect. In contrast, abundance of habitat generalists was higher in isolated compared to connected hedges, with no effect of habitat type (forest edge versus hedge). Species richness as well as abundance of the most abundant habitat generalist Sorex araneus (common shrew), were not affected by habitat type or hedge isolation. Decreasing percentage of bare ground and increasing forest edge/hedge width was associated with increased abundance of forest specialists, while habitat structure was unrelated to species richness or abundance of any other group. Community composition was driven by forest specialists, which exceeded habitat generalist abundance in forest edges and connected hedges, while abundances were similar to each other in isolated hedges. Our results show that small mammal forest specialists prefer forest edges as habitats over hedges, while habitat generalists are able to use unoccupied ecological niches in isolated hedges. Consequently even isolated hedges can be marginal habitats for forest specialists and habitat generalists and thereby may increase regional farmland biodiversity.}, language = {en} } @article{WagnerDrouetTeschnerWolschkeetal.2021, author = {Wagner-Drouet, Eva and Teschner, Daniel and Wolschke, Christine and Sch{\"a}fer-Eckart, Kerstin and G{\"a}rtner, Johannes and Mielke, Stephan and Schreder, Martin and Kobbe, Guido and Hilgendorf, Inken and Klein, Stefan and Verbeek, Mareike and Ditschkowski, Markus and Koch, Martina and Lindemann, Monika and Schmidt, Traudel and Rascle, Anne and Barabas, Sascha and Deml, Ludwig and Wagner, Ralf and Wolff, Daniel}, title = {Comparison of cytomegalovirus-specific immune cell response to proteins versus peptides using an IFN-γ ELISpot assay after hematopoietic stem cell transplantation}, series = {Diagnostics}, volume = {11}, journal = {Diagnostics}, number = {2}, issn = {2075-4418}, doi = {10.3390/diagnostics11020312}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-228843}, year = {2021}, abstract = {Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Measuring CMV-specific cellular immunity may improve the risk stratification and management of patients. IFN-γ ELISpot assays, based on the stimulation of peripheral blood mononuclear cells with CMV pp65 and IE-1 proteins or peptides, have been validated in clinical settings. However, it remains unclear to which extend the T-cell response to synthetic peptides reflect that mediated by full-length proteins processed by antigen-presenting cells. We compared the stimulating ability of pp65 and IE-1 proteins and corresponding overlapping peptides in 16 HSCT recipients using a standardized IFN-γ ELISpot assay. Paired qualitative test results showed an overall 74.4\% concordance. Discordant results were mainly due to low-response tests, with one exception. One patient with early CMV reactivation and graft-versus-host disease, sustained CMV DNAemia and high CD8\(^+\) counts showed successive negative protein-based ELISpot results but a high and sustained response to IE-1 peptides. Our results suggest that the response to exogenous proteins, which involves their uptake and processing by antigen-presenting cells, more closely reflects the physiological response to CMV infection, while the response to exogenous peptides may lead to artificial in vitro T-cell responses, especially in strongly immunosuppressed patients.}, language = {en} }